Gemigliptin: A Novel DPP-4 Inhibitor for Type 2 Diabetes Treatment

 

Gemigliptin

Type 2 diabetes is a chronic metabolic disease characterized by high blood sugar levels as a result of insulin resistance and relative lack of insulin. As per estimates by the World Health Organization (WHO), the global prevalence of diabetes among adults over 18 years of age has risen from 4.7% in 1980 to 8.5% in 2014. While numerous pharmacological agents are available for managing hyperglycaemia in type 2 diabetes, there remains an unmet need for novel treatment options with better safety and efficacy profiles. One such novel agent is gemigliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor developed for the treatment of type 2 diabetes.

Mechanism of Action

It works by inhibiting the dipeptidyl peptidase-4 (DPP-4) enzyme. DPP-4 is an enzyme that breaks down the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulin tropic polypeptide (GIP) rapidly after they are produced and released into the bloodstream by the small intestine. Incretins play a key role in regulating blood glucose levels after meals by stimulating the pancreas to release insulin and suppressing glucagon secretion in a glucose-dependent manner. By inhibiting the inactivation of incretins by DPP-4, it leads to higher levels of active incretin hormones that promote increased insulin secretion and reduced glucagon levels, thereby helping in control of post-meal blood glucose spikes in patients with type 2 diabetes.

Pharmacokinetic Properties

It has favorable pharmacokinetic properties that support its use as an oral anti-diabetic medication. It is rapidly absorbed from the gastrointestinal tract after oral administration, with maximum plasma concentrations achieved within 1-2 hours. The absolute bioavailability of it is approximately 84%. It has low potential for drug interactions as it neither inhibits nor induces the cytochrome P450 enzyme system. The plasma protein binding of it is very weak at around 3%. It is eliminated from systemic circulation primarily through biliary and renal excretion, with an elimination half-life of around 24 hours. Steady state plasma concentrations are reached within 5 days of once-daily dosing.

Efficacy Evaluation in Clinical Trials

The anti-hyperglycemic efficacy and safety profile of it has been evaluated in several phase III randomized controlled trials involving patients with type 2 diabetes.

In a 24-week study comparing 50mg Gemigliptin to sitagliptin 100mg, both treatments significantly reduced HbA1c levels from baseline with a similar mean decrease of around 0.7%. Fasting plasma glucose and 2-hour postprandial glucose levels were also significantly lowered without any difference between groups. Rates of treatment-emergent adverse effects were similar between gemigliptin and sitagliptin arms.

Another study of 52 weeks' duration compared the effects of gemigliptin 50mg to glimepiride 1-4mg in drug-naïve patients with type 2 diabetes. While both treatments significantly lowered HbA1c from baseline, the reduction was greater with gemigliptin (mean decrease 0.95% vs 0.80% with glimepiride). Improvements in fasting plasma glucose and 2-hour postprandial glucose were also more evident with-it. Adverse events including hypoglycemia and body weight gain were less frequent in it compared to glimepiride treatment.

In summary, data from major clinical trials indicates that gemigliptin 50mg once daily is an effective anti-hyperglycemic agent for long-term management of type 2 diabetes, comparable or superior to other DPP-4 inhibitors and sulphonylureas.

Safety and Tolerability

Available evidence from clinical trials and post-marketing surveillance suggests that it has a favorable tolerability and safety profile similar to other DPP-4 inhibitors.

Common adverse events reported with its treatment include upper respiratory tract infection, headache, nausea and gastrointestinal discomfort. However, the incidences of these were similar to placebo and comparable DPP-4 inhibitor treatment groups.

Hypoglycemia is infrequently reported with its monotherapy due to its glucose-dependent mechanism of action. No clinically significant changes have been seen in vital signs, electrocardiography or laboratory parameters with its use.

Long-term safety studies of over 1 year also did not reveal any new or worsening safety issues. It has not been associated with immunogenic potential, pancreatitis, malignant tumor formation or other serious safety concerns inherent to some older anti-diabetic drug classes.

Place in Therapy

It provides an effective and well-tolerated treatment option for type 2 diabetes management. Its favorable pharmacokinetic properties allow once daily oral dosing for convenience. The drug has demonstrated superiority or comparable efficacy to other DPP-4 inhibitors and sulphonylureas in improving glycemic control long-term without major safety issues.

Novel mechanism of action, potent anti-hyperglycemic effects, low risk of hypoglycemia and weight neutral profile, gemigliptin holds promise as an important addition to the current anti-diabetic armamentarium for achieving optimal glycemic control and cardiovascular risk reduction in patients with type 2 diabetes. Its role may lie as an alternative or adjunct to other oral hypoglycemic agents depending on individual patient profiles and treatment requirements.

Get more insights on Gemigliptin